Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterial ribosomal protein inhibitors - Melinta Therapeutics

Drug Profile

Research programme: antibacterial ribosomal protein inhibitors - Melinta Therapeutics

Alternative Names: RX 01413; RX 01423; RX 01445; RX-01; RX-01(a); RX-01(b); RX-01_413; RX-01_423; RX-01_445; RX-02; RX-03; RX-04; RX-04A; RX-04B; RX-04C; RX-04D; RX-05; RX-230; RX-5312; RX-6425; RX-6567; RX-P2177; RX-P2382; RX-P770; RX-P873

Latest Information Update: 30 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rib-X Pharmaceuticals
  • Developer Melinta Therapeutics
  • Class Macrolides; Oxadiazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 23 Apr 2018 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical trials in Bacterial infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 19 Mar 2018 Preclinical development is ongoing for Bacterial infections (Melinta Therapeutics Pipeline; 9235557)
  • 13 Mar 2018 Melinta Therapeutics plans IND-enabling studies for lead ESKAPE compound in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top